Logo

Merck's Keytruda (pembrolizumab) + Eisai's Lenvima (lenvatinib) Receives FDA's Approval for Certain Types of Endometrial Carcinoma

Share this

Merck's Keytruda (pembrolizumab) + Eisai's Lenvima (lenvatinib) Receives FDA's Approval for Certain Types of Endometrial Carcinoma

Shots:

  • The approval is based on P-II KEYNOTE-146/Study 111 assessing Keytruda (200mg- IV- q3w) + Lenvima (20mg- PO- qd) in 108 patients with metastatic endometrial carcinoma that is not microsatellite instability-high (MSI-H)/mismatch repair deficient (dMMR) with diseases progression following prior systemic therapy and are not candidates for curative surgery or radiation
  • The P-II KEYNOTE-146/Study 111 results: ORR (38.3%); CRR (10.6%); PRR (27.7%); median follow up time (18.7mos.). Under Project Orbis- Keytruda + Lenvima regimen is the first to receive simultaneous review decisions in the US- Australia and Canada
  • KEYTRUDA is an anti-PD-1 therapy- act by blocking the interaction between PD-1 and its ligands- PD-L1 and PD-L2 thus activating T lymphocytes affecting both tumor and healthy cells. Lenvima is a kinase inhibitor targeting the activities of VEGF receptor including VEGFR1- VEGFR2 & VEGFR3

Click here to­ read full press release/ article

Ref: Merck | Image: Merck


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions